The critique of the CURE study written by Albers and Amarenco represents the first contribution for the “Emerging Therapies” section of Stroke. In the future, timely invited critiques by acknowledged experts of important and novel articles related to stroke therapy will be provided to the readership. These critiques will overview the results of the therapeutic studies and provide expert commentary and interpretation. These endeavors will hopefully enable the readership to better comprehend the nuances and context of the study and utilize the results for patient care. In addition to these critiques of major articles in other journals related to stroke therapy, several in-depth review articles per year will be sought. These review articles will cover in detail a range of topics related to the gamut of stroke therapies currently available and under development. The intention of the review articles is to provide the readership with a comprehensive, up-to-date, balanced, and detailed overview of important and sometimes controversial stroke therapy topics. Initial review articles of multimodality therapy to prevent stroke, expanding the time window for thrombolytic therapy and anticoagulation after acute stroke, are anticipated. Suggestions for additional topics and authors are welcome. It is hoped that the article critiques and reviews will add to the readership’s enjoyment of Stroke and enhance their knowledge about emerging stroke therapies.
The opinions expressed in this editorial are not necessarily those of the editor or of the American Stroke Association.